news
Eli Lilly's retatrutide leads 19% weight loss in type 2 diabetes
A new Eli Lilly peptide, retatrutide, showed an average 19% body weight loss in people with obesity and type 2 diabetes during trials. This triple-agonist, designed to hit GLP-1, GIP, and glucagon receptors, significantly outpaced previous diabetes weight loss meds in a population notoriously difficult to treat.
A new Eli Lilly peptide, retatrutide, showed an average 19% body weight loss in people with obesity and type 2 diabetes during trials. This triple-agonist, designed to hit GLP-1, GIP, and glucagon receptors, significantly outpaced previous diabetes weight loss meds in a population notoriously difficult to treat.
The architecture take
The new GLP-1/GIP/glucagon triple agonist, retatrutide, is moving the goalposts again for metabolic health. We're past the point of modest 5-10% body weight reductions. Now, you're looking at nearly 19% in a population where weight loss is usually a grind.
This isn't just about shrinking waistlines. That much fat loss has serious downstream effects on blood sugar regulation, insulin sensitivity, and liver health. The interesting part is the glucagon receptor agonism. Glucagon usually raises blood sugar, but here, it seems to boost energy expenditure and fat burning, adding another layer to the peptide's mechanism.
I used to think we'd topped out with dual agonists, but these results show that adding a third target is potent. Watch for this one to reshape the metabolic health market and, frankly, the definition of what's possible for managing type 2 diabetes and obesity.